Frederick Lansigan MD (He/Him)

Cutaneous Lymphoma, Hematologic Oncology

Interim Associate Dean of Diversity, Equity, and Inclusion, Associate Professor, Medicine and Dermatology, Geisel School of Medicine at Dartmouth

Join to view full profile

1 Medical Center DriveLebanon, NH 03756
Phone+1 603-650-5529
Fax+1 603-727-7811

Dr. Lansigan is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lansigan's full profile Already have an account?

Summary

Erick Lansigan, MD is an authority on quality improvement and applies this methodology to promoting Diversity, Equity, Inclusion, and Belonging in education, admissions, recruiting, student experience, workforce development, advocacy, and community engagement, as well as clinical research, health systems, and patient care.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2002 - 2006
State University of New York Downstate Medical Center College of MedicineClass of 2002

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

NH State Medical License 2009 - 2027
ME State Medical License 2020 - 2021
CT State Medical License 2006 - 2008
NY State Medical License 2004 - 2008
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma
COMPLETED
PHASE2
Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
COMPLETED
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment Start of enrollment: 2011 Oct 01
COMPLETED

Publications & Presentations

PubMed

Localized radiation therapy provides more durable disease control than topical steroids in stage IA mycosis fungoides.
Sarah J Lange, Ayushya Ajmani, Sarah M Gonzalez, Xiaoqing Xia, Lesley A Jarvis
Journal of the American Academy of Dermatology. 2026-07-07
Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States.
Charles J Mazof, Vishva Natarajan, Augustos Vrattos, Parth Shah, Frederick Lansigan
Clinical Lymphoma, Myeloma & Leukemia. 2026-04-01
Durable remission of primary testicular diffuse large B-cell lymphoma with secondary cutaneous involvement with chimeric antigen receptor T-cell therapy.
Nicole Trepanowski, Robert E LeBlanc, Caron A Jacobson, Joi B Carter, Frederick Lansigan
JAAD Case Reports. 2026-03-01

Abstracts/Posters

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL)
Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
Frederick Lansigan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?February 4th, 2025
Diversity Among Oncologists Has Not Kept Pace with the U.S. PopulationFebruary 17th, 2022
Oncology Academic Departments Slowly Becoming More DiverseDecember 30th, 2021